Search results
Results from the WOW.Com Content Network
Ribavirin's amide group can make the native nucleoside drug resemble adenosine or guanosine, depending on its rotation. For this reason, when ribavirin is incorporated into RNA, as a base analog of either adenine or guanine, it pairs equally well with either uracil or cytosine , inducing mutations in RNA-dependent replication in RNA viruses.
Ribavirin: Hepatitis C [15] nucleoside analogue reverse transcriptase inhibitor: Rilpivirine (Edurant) [16] HIV Rimantadine: Influenza A: M2 proton channel antagonist Ritonavir: HIV HIV-1 protease inhibitor Saquinavir: HIV Simeprevir (Olysio) Hepatitis C Sofosbuvir: Hepatitis C [17] nucleoside analogue reverse transcriptase inhibitor: Stavudine ...
Ribavirin is one medication which has shown good potential for the treatment of HPIV-3 given recent in-vitro tests (in-vivo tests show mixed results). [12] Ribavirin is a broad-spectrum antiviral, and as of 2012, was being administered to those who are severely immuno-compromised, despite the lack of conclusive evidence for its benefit. [12]
Early and intravenous ribavirin treatment is required for maximal efficacy, and it can produce considerable side effects. [27] Ribavirin has not been evaluated yet in controlled clinical trials. [citation needed] Use of ribavirin during pregnancy is generally not recommended, as some studies indicate the possibility of teratogenic effects. If ...
An interesting variation of this idea is the use of genetically modified cells that can produce custom-tailored ribozymes. This is part of a broader effort to create genetically modified cells that can be injected into a host to attack pathogens by generating specialized proteins that block viral replication at various phases of the viral life ...
In adults, ribavirin is used off-label and is generally reserved for the severely immunocompromised, such as those undergoing hematopoietic stem cell transplants. [ 3 ] Presatovir , an experimental antiviral drug, has shown promising results in clinical trials but has not yet been approved for medical use.
Gastrointestinal disturbances (including mouth ulcers, indigestion, diarrhea, constipation, etc.) Infections (including sinusitis, the flu, sepsis, UTIs, etc.)
Taribavirin has better liver-targeting than ribavirin, and has a shorter life in the body due to less penetration and storage in red blood cells. It is expected eventually to be the drug of choice for viral hepatitis syndromes in which ribavirin is active. These include hepatitis C and perhaps also hepatitis B and yellow fever.